AstraZeneca says docs top driver to patient assistance programs

Share this article:
Doctors and pharmacists drive a third of patients to AstraZeneca's AZ&Me prescription savings program, according to a company survey – a finding that AstraZeneca said highlights the value of its sales reps' interactions with healthcare professionals.

A year-long survey of 12,000 patients who contacted AstraZeneca to inquire about the assistance program found that 35% were referred by healthcare professionals, while another 14% learned of the program from brochures in doctors' offices, hospitals, clinics or pharmacies.

DTC advertising drove 9% of patients to the program, and AstraZeneca websites accounted for another 7%. Patients citing advertising learned abut the program from a variety of newspaper, radio and TV ads, the company said, noting that it was the first in the industry to promote prescription savings programs through product ads. Nexium TV spots started carrying the message in 2005, and the policy was soon broadened to include all AstraZeneca product spots.

Rounding out the survey were those who heard about the program through family or friends (5%) and “Other/don't know” (24%).

The company said its program helped nearly 500,000 patients fill 2.8 million prescriptions last year, resulting in more than $500 million in savings to them.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.